Kidney Disease clinical trials at UCSF
17 in progress, 12 open to eligible people
BION-1301 in Adults With IgA Nephropathy
open to eligible people ages 18 years and up
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
San Francisco, California and other locations
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
open to eligible people ages 18-90
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent …
San Francisco, California and other locations
Belimumab With Rituximab for Primary Membranous Nephropathy
open to eligible people ages 18-75
The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with primary membranous…
San Francisco, California and other locations
Ferric Citrate and Chronic Kidney Disease in Children
open to eligible people ages 6-18
We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two…
San Francisco, California and other locations
VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
open to eligible people ages 10-65
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
San Francisco, California and other locations
DCR-PHXC in Patients With PH1 and ESRD
open to all eligible people
The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
San Francisco, California and other locations
Desensitization of Chronic Kidney Disease in Adult Patients in Need of a Kidney Transplant Who Are Highly Sensitized to Human Leukocyte Antigen
open to eligible people ages 18-70
The primary objective of the study is to assess the safety and tolerability of REGN5459 (Part A) or REGN5458 (Part B) as monotherapy in patients with chronic kidney disease (CKD) who need kidney transplantation and are highly sensitized to human…
San Francisco, California and other locations
Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
open to eligible people ages 18 years and up
The primary objective of this study to evaluate the efficacy of ravulizumab compared with placebo to reduce proteinuria and slow the rate of eGFR decline in adult participants with IgAN who are at risk of disease progression.
San Francisco, California and other locations
Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
open to eligible people ages 6-16
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
San Francisco, California and other locations
Home Blood Pressure (BP) Trial
open to eligible people ages 18 years and up
The main study will be a two arm 10-month, cross-over randomized controlled trial of 200 participants treated with end-stage-kidney-disease treated with in-center hemodialysis in the Seattle and San Francisco area comparing a strategy of targeting…
San Francisco, California and other locations
Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive A Kidney Transplant
open to eligible people ages 18-70
The primary objective of the study is to assess adverse events (AEs) and serious adverse events (SAEs) in kidney transplant recipients previously treated with REGN5459 or REGN5458 in the R5459-RT-1944 study. The secondary objectives of the study are …
San Francisco, California and other locations
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
open to all eligible people
The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a…
San Francisco, California and other locations
Pilot to Examine Risk and Feasibility of Remote Management of BP From CKD Through ESRD
Sorry, currently not accepting new patients, but might later
The transition from chronic kidney disease (CKD) to end-stage renal disease ESRD is a vulnerable and challenging period of time for patients and providers. Suboptimal control of blood pressure is known to be common in patients with the advanced…
San Francisco, California
Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
Sorry, in progress, not accepting new patients
This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSGS. Three…
San Francisco, California and other locations
Expanding and Promoting Alternative Care and kNowledge in Decision-making Trial
Sorry, not currently recruiting here
The goal of this clinical trial is to compare two health system-based approaches for offering kidney failure treatment options to older patients with kidney failure, specifically, to ensure patients are actively involved in a shared decision making…
San Francisco, California and other locations
Long Term Extension Study in Patients With Primary Hyperoxaluria
Sorry, accepting new patients by invitation only
The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients…
San Francisco, California and other locations
Nephrotic Syndrome Study Network
Sorry, not currently recruiting here
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD)…
San Francisco, California and other locations
Our lead scientists for Kidney Disease research studies include Elaine Ku Meyeon Park, MD Paul Brakeman, MD, PhD Chi-yuan Hsu, MD Raymond Hsu.
Last updated: